My­ovan­t's Myfem­bree sN­DA gets new PDU­FA af­ter CRL spec­u­la­tion; In­xMed bags more funds for piv­otal stud­ies

Last month, an­a­lysts spec­u­lat­ed the sN­DA for My­ovant Sci­ences and Pfiz­er’s Myfem­bree could be hit by a CRL af­ter the FDA iden­ti­fied “de­fi­cien­cies.” Now, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER